Economic Burden NSCLC: A Systematic Review of H...

By João L. Carapinha

February 24, 2026

A recently published systematic literature review synthesizes evidence from 50 publications across 43 studies on the economic burden NSCLC in locally advanced (stage IIIB/C) and metastatic (stage IV) non-small cell lung cancer, highlighting high h...
Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
South Africa Health Reform: Navigating Innovations and Challenges for 2026
European Pharma Competitiveness: A Cornerstone for EU Economic Resilience
National HealthTech Access: Transforming NHS Adoption and Equity
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morga...